MedTrace Logo

The Effects of Nebivolol on the NO-system in Patients With Essential Hypertension

NCT01679652 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2014-03-04

No results posted yet for this study

Summary

Investigators want investigate the following hypothesis:

1. Nebivolol increases nitric oxide activity in the systemic circulation and the kidney
2. The increased activity of nitric oxide during nebivolol treatment can be demonstrated by inhibition of NO synthesis with L-NMMA. We expect increased responses in blood pressure and sodium excretion is expected during nebivolol treatment compared to placebo.

Conditions

  • Essential Hypertension

Interventions

DRUG

Nebivolol

Tablet i blinded in capsula

DRUG

placebo

Sponsors & Collaborators

  • Erling Bjerregaard Pedersen

    lead OTHER

Principal Investigators

  • Erling B Pedersen, MD · Department of medical Research, Holstebro Hospital

  • Frank H Mose, MD · Department of Medical Research, Holstebro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01679652 on ClinicalTrials.gov